HT
FULC icon

Headlands Technologies’s Fulcrum Therapeutics FULC Stock Holding History

Headlands Technologies’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Buy
+89,723
New +$546K 0.03% 515

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Headlands Technologies's FULC Position: Q2 2026 in Review

Headlands Technologies opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 89,723 shares worth $328K. The stake represents 0.03% of the portfolio and ranks #515 among its holdings.

155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Headlands Technologies held 89,723 shares of Fulcrum Therapeutics worth $328K as of Q2 2026.
  • Fulcrum Therapeutics was a new Headlands Technologies position in Q2 2026.
  • Fulcrum Therapeutics made up 0.03% of Headlands Technologies's portfolio in Q2 2026, its #515 holding.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.